SAB Biotherapeutics Inc (SABS)

NASD · Healthcare · Biotechnology · USA

SAB Biotherapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G antibodies to treat and prevent immune and autoimmune disorders. The company's lead candidate, SAB-142, targets diabetes using a disease-modifying approach. SAB Biotherapeutics utilizes proprietary technology based on transchromosomic cattle to produce therapeutic antibodies without requiring human plasma donors.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the SAB Biotherapeutics Inc stock.

Our verdict on SABS

Not valued: We cannot value this company yet.

ETFs with the most weight in SABS

10 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than SABS in Biotechnology

129 more in this industry show a wider margin of safety.

Is SABS undervalued or overvalued?

We do not publish a verdict on SABS yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of SABS?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.